The role of LRP8 (ApoER2) in the pathophysiology of the antiphospholipid syndrome

Lupus

Volumn 19, Issue 4, 2010, Pages 389-393

  De Groot, P G ^a   Derksen, R H W M ^a   Urbanus, R T ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antiphospholipid serum; GPIb; LDL receptor

Indexed keywords

BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; BLOOD CLOTTING FACTOR 6; GLYCOPROTEIN IB ALPHA; LIPOCORTIN 2; LOW DENSITY LIPOPROTEIN RECEPTOR PROTEIN 8; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MEGALIN; P SELECTIN GLYCOPROTEIN LIGAND 1; PHOSPHOLIPID ANTIBODY; PROTEIN C; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ANTIPHOSPHOLIPID SYNDROME; CELL ACTIVATION; CLINICAL FEATURE; DIAGNOSTIC TEST; HEMOSTASIS; HOMEOSTASIS; HUMAN; IN VITRO STUDY; MEDIATOR; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; PROTEIN PROTEIN INTERACTION; PROTEIN VARIANT; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; THROMBOSIS;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; BLEEDING TIME; BLOOD COAGULATION TESTS; HEMOSTASIS; HUMANS; RECEPTORS, LIPOPROTEIN; THROMBOSIS;

EID: 77951213979     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309360542     Document Type: Review

References (49)

1. Miyakis S., Lockshin MD, Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006 ; 4: 295-306.
2. Arnout J., Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost 2003 ; 1: 931-942.
3. Urbanus RT, Derksen RH, de Groot PG Current insight into diagnostics and pathophysiology of the antiphospholipid syndrome. Blood Rev 2008 ; 22: 93-105.
4. Galli M., Luciani D., Bertolini G., Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003 ; 101: 1827-1832. (Pubitemid 36237580)
5. Simmelink MJA, Derksen Rhwm, Arnout J., de Groot PG A simple method to discriminate between β2-glycoprotein- and prothrombin-dependent lupus anticoagulants. J Thromb Haemost 2003 ; 1: 740-747.
6. de Laat HB, Derksen Rhwm, Urbanus RT, Roest M., de Groot PG β2-Glycoprotein I dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004 ; 104: 3598-3602. (Pubitemid 39564433)
7. Iverson GM, Reddel S., Victoria EJ, et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002 ; 169: 7097-7103. (Pubitemid 36899298)
8. De Laat B., Derksen RH, Urbanus RT, de Groot PG IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β2-glycoprotein I cause LAC and their presence correlates strongly with thrombosis. Blood 2005 ; 105: 1540-1545. (Pubitemid 40223671)
9. Ioannou Y., Pericleous C., Giles I., Latchman DS, Isenberg DA, Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta2-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007 ; 56: 280-290. (Pubitemid 46106202)
10. Ioannou Y., Romay-Penabad Z., Pericleous C., et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost 2009 ; 7: 833-842.
11. Lozier J., Takahashi N., Putnam FW Complete amino acid sequence of human plasma beta 2-glycoprotein I. Proc Natl Acad Sci USA 1984 ; 81: 3640-3644. (Pubitemid 14087780)
12. Bouma B., de Groot PG, van der Elsen JMH, et al. Adhesion mechanism of human β2-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999 ; 18: 5166-5174. (Pubitemid 29465567)
13. A?ar C., de Groot PG, Levels JH, Marquart JA, Meijers JC Beta-glycoprotein I is incorrectly named apolipoprotein H. J Thromb Haemost 2009 ; 7: 235-236.
14. de Laat B., Derksen Rhwm, van Lummel M., Pennings MT, de Groot PG Pathogenic anti-β2-glycoprotein I antibodies recognize domain I of β2-glycoprotein I only after a conformational change. Blood 2006 ; 107: 1916-1924. (Pubitemid 43289372)
15. Biasiolo A., Rampazzo P., Brocco T., et al. Anti-beta2 glycoprotein I-beta2 glycoprotein immune complexes in patients with antiphospholipid syndrome and other autoimmune diseases. Lupus 1999 ; 8: 121-126.
16. Hoeg JM, Segal P., Gregg RE, et al. Characterization of plasma lipids and lipoproteins in patients with beta 2-glycoprotein I (apolipoprotein H) deficiency. The fasting plasma lipids, lipoproteins, and apolipoproteins were evaluated in 5 subjects. Atherosclerosis 1985 ; 55: 25-34.
17. Sheng Y., Reddel SW, Herzog H., et al. Impaired thrombin generation in beta 2-glycoprotein I null mice. J Biol Chem 2001 ; 276: 13817-13821. (Pubitemid 37391759)
18. Del Papa N., Guidali L., Sala A., et al. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum 1997 ; 40: 551-561. (Pubitemid 27123672)
19. de Groot PG, Horbach DA, Derksen RH Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. Lupus 1996 ; 5: 488-493.
20. Wahl D., Membre A., Perret-Guillaume C., Regnault V., Lecompte T. Mechanisms of antiphospholipid-induced thrombosis: effects on the protein C system. Curr Rheumatol Rep 2009 ; 11: 77-81.
21. Lutters BCH, Derksen Rhwm, Tekelenburg WL, Lenting PJ, Arnout J., de Groot PG Dimers of β2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2. J Biol Chem 2003 ; 278: 33831-33838.
22. Meroni PL, Gerosa M., Raschi E., Scurati S., Grossi C., Borghi MO Updating on the pathogenic mechanisms 5 of the antiphospholipid antibodies-associated pregnancy loss. Clin Rev Allergy Immunol 2008 ; 34: 332-337.
23. Wolberg AS, Roubey RA Mechanisms of autoantibody-induced monocyte tissue factor expression. Thromb Res 2004 ; 114: 391-396. (Pubitemid 39422571)
24. Satta N., Dunoyer-Geindre S., Reber G., et al. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood 2007 ; 109: 1507-1514. (Pubitemid 46239583)
25. Pierangeli SS, Vega-Ostertag ME, Raschi E., et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis 2007 ; 66: 1327-1333. (Pubitemid 47492476)
26. Romay-Penabad Z., Montiel-Manzano MG, Shilagard T., et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood 2009 ; 114: 3074-3083.
27. Urbanus RT, Pennings MT, Derksen RH, de Groot PG Platelet activation by dimeric beta2-glycoprotein I requires signalling via both glycoprotein Ib alpha and apolipoprotein E receptor 2. J Thromb Haemost 2008 ; 6: 1405-1412.
28. Pennings MTT, van Lummel M., Derksen Rhwm, et al. Interaction of β2-glycoprotein I with members of the low density lipoprotein receptor family. J Thromb Haemost 2006 ; 4: 1680-1690. (Pubitemid 44144793)
29. May P., Woldt E., Matz RL, Boucher P. The LDL receptor-related protein (LRP) family: an old family of proteins with new physiological functions. Ann Med 2007 ; 39: 219-228. (Pubitemid 46676481)
30. Mayer H., Duit S., Hauser C., Schneider WJ, Nimpf J. Reconstitution of the Reelin signaling pathway in fibroblasts demonstrates that Dab1 phosphorylation is independent of receptor localization in lipid rafts. Mol Cell Biol 2006 ; 26: 19-27.
31. Riddell DR, Vinogradov DV, Stannard AK, Chadwick N., Owen JS Identification and characterization of LRP8 (apoER2) in human blood platelets. J Lipid Res 1999 ; 40: 1925-1930. (Pubitemid 29477264)
32. Korschineck I., Ziegler S., Breuss J., et al. Identification of a novel exon in apolipoprotein E receptor 2 leading to alternatively spliced mRNAs found in cells of the vascular wall but not in neuronal tissue. J Biol Chem 2001 ; 276: 13192-13197. (Pubitemid 37385248)
33. Yang XV, Banerjee Y., Fern'ndez JA, et al. Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signalling in U937 cells. Proc Natl Acad Sci USA 2009 ; 106: 274-279.
34. Pennings MT, Derksen Rhwm, Urbanus RT, Tekelenburg WL, Hemrika W., de Groot PG Platelets express three different splice variants of ApoER2 that are all involved in signalling. J Thromb Haemost 2007 ; 5: 1538-1544.
35. Shen GQ, Li L., Girelli D., et al. An LRP8 variant is associated with familial and premature coronary artery disease and myocardial infarction. Am J Hum Genet 2007 ; 81: 780-791. (Pubitemid 47596545)
36. Wang L., Wang X., Laird N., Zuckerman B., Stubblefield P., Xu X. Polymorphism in maternal LRP8 gene is associated with fetal growth. Am J Hum Genet 2006 ; 78: 770-777.
37. Urbanus R., Derksen Rhwm, de Groot PG Platelets and the antiphospholipid syndrome. Lupus 2008 ; 17: 888-894.
38. Somanath PR, Malinin NL, Byzova TV Cooperation between integrin ±vβ3 and VEGFR2 in angiogenesis. Angiogenesis 2009 ; 12: 177-185.
39. Pennings MT, Derksen RH, van Lummel M., et al. Platelet adhesion to dimeric beta2-glycoprotein-I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and APOER2. J Thromb Haemost 2007 ; 5: 369-377.
40. White TC, Berny MA, Tucker EI, et al. Protein C supports platelet binding and activation under flow: role of glycoprotein Ib and apolipoprotein E receptor 2. J Thromb Haemost 2008 ; 6: 995-1002.
41. White-Adams TC, Berny MA, Tucker EI, et al. Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2). Art Thromb Vasc Biol 2009 ; 29: 1602-1607.
42. Liest'l S., Sandset PM, Mowinckel MC, Wisl'ff F. Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants. J Thromb Haemost 2007 ; 5: 2204-2210.
43. Weiler H., Ruf W. Activated protein C in sepsis: the promise of nonanticoagulant activated protein C. Curr Opin Hematol 2008 ; 15: 487-493.
44. Kim HM, Park BS, Kim JI, et al. Crystal structure of the TLR4- MD-2 complex with bound endotoxin antagonist eritoran. Cell 2007 ; 130: 906-917.
45. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000 ; 342: 696-701. (Pubitemid 30131422)
46. Sugi T., McIntyre JA Certain autoantibodies to phosphatidylethanolamine (aPE) recognize factor XI and prekallikrein independently or in addition to the kininogens. J Autoimmun 2001 ; 17: 207-214. (Pubitemid 33108756)
47. Shi T., Iverson GM, Qi JC, et al. Beta 2-glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I. Proc Natl Acad Sci USA 2004 ; 101: 3939-3944. (Pubitemid 38381081)
48. Urbanus RT, de Groot PG, Derksen RH Reply on prolonged bleeding time and lupus anticoagulant: a second paradox in the antiphospholipid syndrome. Arthritis Rheum 2005 ; 52: 1949-1950.
49. Salmon J., de Groot PG Pathogenic role of antiphospholipid antibodies. Lupus 2008 ; 17: 405-411. (Pubitemid 351798717)